Company Profile

Dekk-Tec Inc is developing new therapies and clinical candidates for the management of cancer, allied diseases, pre-cancerous lesions and women's health issues. The firm is evaluating a novel phenylhydrazone as an immune modulator for treating anogenital cancer associated with human papilloma virus infection. DM-CHOC-PEN, the firm’s lead proprietary investigational anticancer agent, is able to be administered intravenously, cross the blood brain barrier and localize in cancer tissue. Many cancer drugs are not able to cross this barrier and thus must be given intra-cranially, which can cause significant toxicity with only modest efficacy. Dekk-Tec's product has favorable safety, toxicity and PK/PD profiles with superior efficacy to available therapies in pre-clinical studies. As such, DM-CHOC-PEN represents a significant new cancer therapy opportunity to address a large unmet medical need. Dekk-Tec has previously licensed two of their pipeline products to Biotech/Pharmaceutical companies